Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11754494 | 0.82 | DDB1 (0.47) | DDB1CRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL11220100 | 0.82 | CRBN (0.47) | DDB1CRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL10960844 | 0.82 | NR1H2 (0.34) | DDB1CRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL19463659 | 0.82 | DDB1 (0.51) | DDB1CRBNALDH1A1HPGDGAA | |
| SCHEMBL11756918 | 0.80 | DDB1 (0.51) | DDB1CRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL11757714 | 0.80 | DDB1 (0.51) | DDB1CRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL11754928 | 0.77 | NR3C1 (0.40) | CRBNMEN1KMT2AALDH1A1POLB | |
| SCHEMBL11755863 | 0.76 | LDHA (0.38) | MAPT | |
| SCHEMBL10961455 | 0.76 | DDB1 (0.49) | DDB1CRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL11757038 | 0.76 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997046-B1 | CELLULOSE ETHERS ESTERIFIED WITH DICARBOXYLIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-9890221-B2 | Cellulose ethers esterified with dicarboxylic acid | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160289344-A1 | CELLULOSE ETHERS ESTERIFIED WITH DICARBOXYLIC ACID | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2016-10-06 | — | — | US | disclosed |
| EP-2997046-A1 | CELLULOSE ETHERS ESTERIFIED WITH DICARBOXYLIC ACIDS | Dow Global Technologies LLC (US) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014186185-A1 | CELLULOSE ETHERS ESTERIFIED WITH DICARBOXYLIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-11-20 | — | — | WO | disclosed |
| EP-1991526-B1 | Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (PBR) | HAMMERSMITH IMANET LTD (GB) | 2014-02-12 | — | — | EP | disclosed |
| US-8506932-B2 | Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (PBR) | HAMMERSMITH IMANET LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20090220420-A1 | TETRACYCLIC INDOLE DERIVATIVES AS IN VIVO IMAGING AGENTS AND HAVING PERIPHERALBENZODIAZEPINE RECEPTOR AFFINITY (PBR) | GE HEALTHCARE LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1991526-A1 | TETRACYCLIC INDOLE DERIVATIVES AS IN VIVO IMAGING AGENTS AND HAVING PERIPHERALBENZODIAZEPINE RECEPTOR AFFINITY (PBR) | Hammersmith Imanet, Ltd (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007057705-A1 | TETRACYCLIC INDOLE DERIVATIVES AS IN VIVO IMAGING AGENTS AND HAVING PERIPHERALBENZODIAZEPINE RECEPTOR AFFINITY (PBR) | HAMMERSMITH IMANET LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| US-4009278-A | Antimicrobial composition and method containing N-(3,5-dihalophenyl)-imide compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289344-A1 | CELLULOSE ETHERS ESTERIFIED WITH DICARBOXYLIC ACID | SCO2, SUCNR1, MCCC2 | DDB1 2899/4885CRBN 1087/4885F2 1279/4885 |
| US-20090220420-A1 | TETRACYCLIC INDOLE DERIVATIVES AS IN VIVO IMAGING AGENTS AND HAVING PERIPHERALBENZODIAZEPINE RECEPTOR AFFINITY (PBR) | KIT, CNR1, CNR2 | DDB1 2638/4885CRBN 569/4885F2 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.